Yet Vitravene, a locally injected drug, fell short of proving antisense's broader promise, and it never took off because of competition from AIDS cocktails.
For eight years Isis survived without a substantial product, and in 1998 it won federal approval of Vitravene, an eye infection drug for AIDS patients.